A5056378861- Synthesis and biological activity
- Cancer Mechanisms and Therapy
- Lung Cancer Treatments and Mutations
- Synthesis and Characterization of Heterocyclic Compounds
- Enzyme function and inhibition
- PI3K/AKT/mTOR signaling in cancer
Dana-Farber Cancer Institute
2021-2023
Center for Orthopaedics
2023
MET-targeted therapies are clinically effective in MET-amplified and MET exon 14 deletion mutant (METex14) non-small cell lung cancers (NSCLCs), but their efficacy is limited by the development of drug resistance. Structurally distinct tyrosine kinase inhibitors (TKIs) (type I/II) have been developed or under clinical evaluation, which may overcome MET-mediated resistance mechanisms. In this study, we assess secondary mutations likely to emerge response treatment with single-agent...
<p>Application of Bliss independence to test for synergy effect TKI combination treatment in vivo</p>
<p>Supplementary Figures S1-3; Supplementary Tables S1-3</p>
<div>Abstract<p>MET-targeted therapies are clinically effective in <i>MET</i>-amplified and <i>MET</i> exon 14 deletion mutant (<i>MET</i>ex14) non–small cell lung cancers (NSCLCs), but their efficacy is limited by the development of drug resistance. Structurally distinct MET tyrosine kinase inhibitors (TKIs) (type I/II) have been developed or under clinical evaluation, which may overcome MET-mediated resistance mechanisms. In this study, we...
<div>Abstract<p>MET-targeted therapies are clinically effective in <i>MET</i>-amplified and <i>MET</i> exon 14 deletion mutant (<i>MET</i>ex14) non–small cell lung cancers (NSCLCs), but their efficacy is limited by the development of drug resistance. Structurally distinct MET tyrosine kinase inhibitors (TKIs) (type I/II) have been developed or under clinical evaluation, which may overcome MET-mediated resistance mechanisms. In this study, we...
<p>Supplementary Figures S1-3; Supplementary Tables S1-3</p>
<p>Application of Bliss independence to test for synergy effect TKI combination treatment in vivo</p>